Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
News - Targeted Oncology
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
The Targeted Pulse: Discover Key FDA Actions in Leukemia and …
8 hours ago · Revumenib Crosses the Finish Line For KMT2A-Rearranged Acute Leukemia. Revumenib (SNDX-5613) has received FDA approval for the treatment of adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged acute leukemia.This approval is based on data from the phase 1/2 AUGMENT-101 trial (NCT04065399), which evaluated the efficacy and safety of the drug in a total of 94 patients ...
LYMPHOMAS - Targeted Oncology
October 1st 2024. During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.
Breast Cancer | Oncology News & Insights - Targeted Oncology
November 13th 2024. During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC
2 days ago · The FDA has accepted a supplemental new drug application (sNDA) seeking expanded indication for darolutamide (Nubeqa) for use in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Data from the phase 3 ARANOTE ...
Updated Zanidatamab Data Shows Durable Response in Biliary …
1 day ago · Updated data from the phase 2b HERIZON-BTC-01 trial (NCT04466891) revealed that zanidatamab (ZW25) given to patients with pretreated, advanced, unresectable, or metastatic HER2-amplified (HER2+) biliary tract cancer (BTC) led to a clinical benefit. 1 Longer-term follow-up data from the study presented during the 2024 American Society of Clinical Oncology Annual Meeting showed that the ...
About Us - Targeted Oncology
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Less Toxic, More Personalized Treatments on the Horizon in …
Sep 12, 2024 · Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.
TNBC Vaccine Shows Promising Safety, Immune Response in …
2 days ago · An investigational breast cancer vaccine for triple-negative breast cancer (TNBC) showed encouraging results, with over 70% of patients exhibiting protocol-defined immune responses, according to findings from a phase 1 trial (NCT04674306) presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. 1 The α-lactalbumin vaccine demonstrated safety, tolerability, and immune ...